ORPHA:263310
Thymoma type A
Publications
653
87.9th percentile
Trials
0
Interventional, condition-specific
Researchers
1,117
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0002588
- UMLS:C1266091
- NCIT:C6454
Additional Mondo synonyms (6)
medullary thymoma · primary thymic epithelial neoplasm type A · primary thymic epithelial tumor type A · primary thymic epithelial tumour type A · spindle cell thymoma · thymoma type A
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
653 matched papers (390 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 74 for broader category thymoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
653
653 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
653 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
390 in the last 10 years · medium confidence · 87.9th percentile (publications denominator)
Phrase hits: 653 · MeSH hits: 0
Who's working on it?
1,117
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Zhang J7 papers · 2026
School of Pet Science and Technology, Jiangsu Agricultural and Animal Husbandry Technology Vocational College, Taizhou, China.
Papers in Europe PMC - 02Moran CA6 papers · 2026
Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030.
Papers in Europe PMC - 03Weissferdt A6 papers · 2026
Department of Pathology, MD Anderson Cancer Center, Houston, TX 77030, USA. aweissferdt@doctors.org.uk
Papers in Europe PMC - 04Wang L5 papers · 2024
Department of Pathology, First Hospital of China Medical University, Shenyang, China.
Papers in Europe PMC - 05Liu J4 papers · 2026
School of Computer and Information Technology, Beijing Jiaotong University, Beijing, China.
Papers in Europe PMC - 06Liu Y4 papers · 2025
Department of Hematology-Oncology, Chongqing University Cancer Hospital, No.181 HanYu Road, Chongqing, 400030, China. liuyao77@cqu.edu.cn.
Papers in Europe PMC - 07Suster S4 papers · 2025
Department of Pathology, Medical College of Wisconsin, Milwaukee, WI.
Papers in Europe PMC - 08Chen H3 papers · 2024
Department of Pathology, China-Japan Friendship Hospital, Beijing, China.
Papers in Europe PMC - 09Chen L3 papers · 2026
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 156 Wujiadun, Jianghan District, Wuhan, Hubei Province, 430022, China.
Papers in Europe PMC - 10Li J3 papers · 2024
Department of Hematology-Oncology, Chongqing University Cancer Hospital, No.181 HanYu Road, Chongqing, 400030, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 74 trials are registered for thymoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
74 interventional trials matched thymoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: thymoma
74
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05104736·RECRUITING·PT-112 in Subjects With Thymoma and Thymic Carcinoma
Conditions: Thymic Epithelial Tumor · Recurrent Thymoma · Thymic Cancer·Matched via name phrase
- NCT02633553·RECRUITING·Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Conditions: Thymoma·Matched via name phrase
- NCT04731610·RECRUITING·Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)
Conditions: Thymoma Malignant Recurrent·Matched via name phrase
- NCT07231523·NOT YET RECRUITING·EFG vs IVIG in TAMG
Conditions: Efgartigimod · Intravenous Immunoglobulin · Myasthenia Gravis Associated With Thymoma·Matched via name phrase
- NCT06248515·RECRUITING·A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Conditions: Thymoma · Thymic Carcinoma·Matched via name phrase
- NCT06838910·RECRUITING·Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
Conditions: Thymic Carcinoma · Thymoma·Matched via name phrase
- NCT07132918·RECRUITING·HEARTS Trial for Thoracic Cancers
Conditions: Non-Small Cell Lung Cancer (Stage III) · Esophageal Cancer Stage I-III · Esophagogastric Cancer Stage I-III · Thymoma and Thymic Carcinoma Stage II-III·Matched via name phrase
- NCT07693855·NOT YET RECRUITING·Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
Conditions: Thymus Neoplasms · Thymic Epithelial Tumor · Thymoma · Thymic Carcinoma·Matched via name phrase
- NCT07463313·NOT YET RECRUITING·6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Conditions: Thymoma and Thymic Carcinoma·Matched via name phrase
- NCT06186726·RECRUITING·Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Conditions: Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy·Matched via name phrase
- NCT03295227·RECRUITING·Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
Conditions: Stage III Thymoma AJCC v8 · Stage IIIA Thymoma AJCC v8 · Stage IIIB Thymoma AJCC v8 · Stage IV Thymoma AJCC v8·Matched via name phrase
- NCT06029621·RECRUITING·Robot-assisted vs VATS for Thymoma
Conditions: Thymoma·Matched via name phrase
- NCT06924619·RECRUITING·Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
Conditions: Locally Advanced Thymoma·Matched via name phrase
- NCT06730308·RECRUITING·Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Conditions: Thymoma·Matched via name phrase
- NCT07598955·RECRUITING·Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Conditions: B2 Thymoma · Thymic Carcinoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Thymoma type A" OR "medullary thymoma" OR "primary thymic epithelial neoplasm type A" OR "primary thymic epithelial tumor type A" OR "primary thymic epithelial tumour type A" OR "spindle cell thymoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Thymoma type A" OR "medullary thymoma" OR "primary thymic epithelial neoplasm type A" OR "primary thymic epithelial tumor type A" OR "primary thymic epithelial tumour type A" OR "spindle cell thymoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"thymoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:18:53.305Z
